ImmunologybioRxivPreprint
Allogeneic CRISPR-Engineered CAR-T Cells Drive Potent Antitumor Activity in Solid Tumors
Mingyu Huo, Dan Li, Nan Li…·Mitchell Ho
This study develops allogeneic CRISPR-engineered CAR-T cells targeting GPC2 and GPC3, showing potent antitumor activity in solid tumors with repeated dosing and no toxicity.